Minerva IPO Presentation Deck slide image

Minerva IPO Presentation Deck

Minerva ES Clinical Trials Overview Minerva Single Arm Study Endpoint Study patients ese Reduction in blood loss assessed by Pictorial Blood Loss Assessment Chart (PBLAC)¹ 110 patients • Enrolled across seven centers in Canada, Hungary, and Mexico Minerva Randomized Controlled Trial Reduction in blood loss assessed by Alkaline Hematin (AH) Method² 153 patients • Randomized 2:1 • Enrolled across 13 centers in the United States, Canada, and Mexico *Pictorial Blood Loss Assessment Chart (PBLAC) is a time-tested and validated menstrual diary scoring system developed by Higham. Patient success is defined as a reduction in PBLAC score from > 150 pre-treatment to a PBLAC score of ≤ 75 without incidence of acute treatment failure or additional therapy 2 Alkaline Hematin (AH) method is a validated, quantitative process of measuring blood loss by assessing used sanitary products. Patient success is defined as a reduction in AH value 2 160ml to AH value s 80ml without incidence of acute treatment failure or additional therapy 18
View entire presentation